Richard Scott Struthers - 12 Oct 2022 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Role: President & CEO, Director
Signature: /s/ Marc Wilson, as attorney-in-fact
Issuer symbol: CRNX
Transactions as of: 12 Oct 2022
Net transactions value: +$21,201
Form type: 4
Filing time: 14 Oct 2022, 16:55:04 UTC
Previous filing: 15 Apr 2022
Next filing: 03 Mar 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CRNX	Common Stock	Options Exercise	$21,201	+11,100	+19%	$1.91^*	68,500	12 Oct 2022	Direct
holding	CRNX	Common Stock						730,805	12 Oct 2022	By Family Trust 1
holding	CRNX	Common Stock						1,000	12 Oct 2022	By Spouse
holding	CRNX	Common Stock						90,000	12 Oct 2022	By Family Trust 2
holding	CRNX	Common Stock						90,000	12 Oct 2022	By Family Trust 3
holding	CRNX	Common Stock						90,000	12 Oct 2022	By Family Trust 4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CRNX	Incentive stock option (Right to Buy)	Options Exercise	$0	-11,100	-6.4%	$0.000000	161,270	12 Oct 2022	Common Stock	11,100	$1.91	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	1/48th of the shares subject to the option vested on April 16, 2018, and 1/48th of the shares subject to the option vested monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.